Literature DB >> 17594065

[Vasopressin as a rescue vasopressor agent. Treatment of selected cardiogenic shock states].

V D Mayr1, G Luckner, S Jochberger, V Wenzel, W R Hasibeder, M W Dünser.   

Abstract

Vasodilatory shock is the most common form of shock in the critically ill patient. As a consequence of overwhelming and prolonged mediator production, vasodilatory shock can be the common final pathway of primary non-vasodilatory shock (e.g. cardiogenic or hypovolemic shock). A supplementary infusion of arginine vasopressin (AVP) showed beneficial effects on hemodynamics and potentially on the outcome in patients with vasodilatory shock due to sepsis or after major surgery. In this case series, successful administration of AVP in three surgical patients with primary cardiogenic shock forms is reported. The hemodynamic effects of AVP were comparable to those AVP-induced alterations described in septic shock and seem to be predominantly mediated by potent vasoconstriction and the facilitated reduction of higher, potentially toxic catecholamine doses. Thus, an AVP-induced decrease in heart rate and pulmonary arterial pressures may be particularly beneficial in patients with impaired cardiac function.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17594065     DOI: 10.1007/s00101-007-1227-4

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  20 in total

Review 1.  The pathogenesis of vasodilatory shock.

Authors:  D W Landry; J A Oliver
Journal:  N Engl J Med       Date:  2001-08-23       Impact factor: 91.245

Review 2.  Update on the management of cardiogenic shock.

Authors:  Henry J Mann; Paul E Nolan
Journal:  Curr Opin Crit Care       Date:  2006-10       Impact factor: 3.687

3.  Effect of vasopressin on hemodynamics in patients with refractory cardiogenic shock complicating acute myocardial infarction.

Authors:  Sanjit Jolly; Gary Newton; Eric Horlick; Peter H Seidelin; Heather J Ross; Mansoor Husain; Vladimir Dzavik
Journal:  Am J Cardiol       Date:  2005-10-21       Impact factor: 2.778

4.  Vasopressin pressor hypersensitivity in vasodilatory septic shock.

Authors:  D W Landry; H R Levin; E M Gallant; S Seo; D D'Alessandro; M C Oz; J A Oliver
Journal:  Crit Care Med       Date:  1997-08       Impact factor: 7.598

Review 5.  Arginine vasopressin in 316 patients with advanced vasodilatory shock.

Authors:  Günter Luckner; Martin W Dünser; Stefan Jochberger; Viktoria D Mayr; Volker Wenzel; Hanno Ulmer; Stefan Schmid; Hans Knotzer; Werner Pajk; Walter Hasibeder; Andreas J Mayr; Barbara Friesenecker
Journal:  Crit Care Med       Date:  2005-11       Impact factor: 7.598

6.  The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: a retrospective analysis.

Authors:  M W Dünser; A J Mayr; H Ulmer; N Ritsch; H Knotzer; W Pajk; G Luckner; N J Mutz; W R Hasibeder
Journal:  Anesth Analg       Date:  2001-07       Impact factor: 5.108

7.  Terlipressin dose response in healthy and endotoxemic sheep: impact on cardiopulmonary performance and global oxygen transport.

Authors:  Martin Westphal; Henning Stubbe; Andreas Wilhelm Sielenkämper; Reka Borgulya; Hugo Van Aken; Christian Ball; Hans-Georg Bone
Journal:  Intensive Care Med       Date:  2002-11-30       Impact factor: 17.440

Review 8.  Management of vasodilatory shock: defining the role of arginine vasopressin.

Authors:  Martin W Dunser; Volker Wenzel; Andreas J Mayr; Walter R Hasibeder
Journal:  Drugs       Date:  2003       Impact factor: 9.546

9.  Arginine vasopressin induces endothelium-dependent vasodilatation of the pulmonary artery. V1-receptor-mediated production of nitric oxide.

Authors:  P R Evora; P J Pearson; H V Schaff
Journal:  Chest       Date:  1993-04       Impact factor: 9.410

10.  Enhanced pulmonary arterial dilation to arginine vasopressin in chronically hypoxic rats.

Authors:  M R Eichinger; B R Walker
Journal:  Am J Physiol       Date:  1994-12
View more
  5 in total

Review 1.  Anesthesia in swine : optimizing a laboratory model to optimize translational research.

Authors:  D Pehböck; H Dietrich; G Klima; P Paal; K H Lindner; V Wenzel
Journal:  Anaesthesist       Date:  2015-01       Impact factor: 1.041

2.  Vasopressin and ischaemic heart disease: more than coronary vasoconstriction?

Authors:  Pierre Asfar; Peter Radermacher
Journal:  Crit Care       Date:  2009-07-22       Impact factor: 9.097

3.  Vasopressor stays vasopressor and inotrope stays inotrope!

Authors:  Günter Luckner; Walter R Hasibeder; Martin W Dünser
Journal:  Crit Care       Date:  2008-04-14       Impact factor: 9.097

Review 4.  Year in review 2009: Critical Care--shock.

Authors:  Wolfgang Stahl; Hendrik Bracht; Peter Radermacher; Jörg Thomas
Journal:  Crit Care       Date:  2010-11-05       Impact factor: 9.097

5.  Vasopressin in vasodilatory shock: is the heart in danger?

Authors:  Balázs Hauser; Pierre Asfar; Enrico Calzia; Régent Laporte; Michael Georgieff; Peter Radermacher
Journal:  Crit Care       Date:  2008-04-10       Impact factor: 9.097

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.